The importance of subclonal genetic events in MDS

Blood

Volumn 122, Issue 22, 2013, Pages 3550-3551

  Bejar, Rafael ^a   Abdel Wahab, Omar ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN; PROTEIN; PROTEIN P53; SRSF2 PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER GROWTH; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; DEMETHYLATION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA METHYLATION; EXOME; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; ONCOGENE C KIT; ONCOGENE N RAS; OVERALL SURVIVAL; PATHOGENESIS; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RNA SPLICING; SCORING SYSTEM; SEQUENCE ANALYSIS; SOMATIC MUTATION; WHOLE GENOME SEQUENCING;

EID: 84888253087     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-527655     Document Type: Review

References (9)

1. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-3627.
2. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-2506.
3. Bejar R, Stevenson K, Caughey B, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30(27):3376-3382.
4. Murphy DM, Bejar R, Stevenson K, et al. NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. Leukemia. 2013.
5. Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366(12):1090-1098.
6. Walter MJ, Shen D, Shao J, et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia. 2013;27(6):1275-1282.
7. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
8. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714-726.
9. Murphy DM, Bejar R, Stevenson K, et al. NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes [published online ahead of print May 27, 2013]. Leukemia. doi:10.1038/leu.2013.160.